ArticleEmerging microbes & infections2021
The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.
Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- VP1-141 is a determinant of a Vero cell-adapted Coxsackievirus A10 for vaccine development.PLoS neglected tropical diseases · 2026Article
- Detection of echovirus 7 in effluent sewage treatment plant Ahvaz city, Iran.Iranian journal of microbiology · 2026Article
- The gut virome and regulatory T cell axis in health and systemic disease.Microbiome research reports · 2026Review
- Evaluation of enterovirus A71 vaccine effectiveness against pediatric hand, foot, and mouth disease caused by enterovirus A71 virus in Tianjin, China, 2016-2023: A test-negative design case-control study.Human vaccines & immunotherapeutics · 2025Article
- Article
- Enterovirus A71 priorities, challenges, and future opportunities in humoral immunity and vaccine development.NPJ vaccines · 2025Review
- Using COVID-19 pandemic perturbation to model RSV-hMPV interactions and potential implications under RSV interventions.Nature communications · 2025Article
- Epidemiology of hand, foot, and mouth disease outbreaks before and during availability of EV-A71 vaccine in China's mainland: analysis of outbreak surveillance data from 2011 to 2023.The Lancet regional health. Western Pacific · 2025Article
- Enteroviruses Activate Cellular Innate Immune Responses Prior to Adaptive Immunity and Tropism Contributes to Severe Viral Pathogenesis.Microorganisms · 2025Review
- Genetic characterization of human enterovirus A71 genotypes C4 and B5 Circulating in Qingdao City, Shandong province, China, from 2023 to 2024.Frontiers in cellular and infection microbiology · 2025Article
- Effectiveness of EV-A71 Vaccine and Its Impact on the Incidence of Hand, Foot and Mouth Disease: A Systematic Review.Vaccines · 2024Review
- Analysis of the Impact of Inactivated A71 Vaccine on the Incidence of Hand-Foot-Mouth Disease in Pudong New Area, Shanghai.Vaccines · 2024Article
- Analysis of miRNAs involved in mouse brain injury upon Coxsackievirus A6 infection.Frontiers in cellular and infection microbiology · 2024Article
- Spatiotemporal patterns and risk mapping of provincial hand, foot, and mouth disease in mainland China, 2014-2017.Frontiers in public health · 2024Article
- Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system.Virus research · 2023Article
- Molecular characterization of coxsackievirus B5 from the sputum of pneumonia children patients of Kunming, Southwest China.Virology journal · 2023Article
- The impact of the COVID-19 pandemic on the number of hand, foot, and mouth disease due to enterovirus 71 infectionsThe Journal of infection · 2023Article
- Factors related to the mortality risk of severe hand, foot, and mouth diseases (HFMD): a 5-year hospital-based survey in Guangxi, Southern China.BMC infectious diseases · 2023Article
- A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection.Current research in microbial sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus A71 (EV-A71) inactivated vaccines have been widely inoculated among children in Kunming City after it was approved. However, there was a large-scale outbreak of Enteroviruses (EVs) infection in Kunming, 2018. The epidemiological characteristics of HFMD and EVs were analysed during 2008-2018, which are before and three years after EV-A71 vaccine starting to use. The changes in infection spectrum were also investigated, especially for severe HFMD in 2018. The incidence of EV-A71 decreased dramatically after the EV-A71 vaccine starting use. The proportion of non-CV-A16/EV-A71 EVs positive patients raised to 77.17-85.82%, while, EV-A71 and CV-A16 only accounted for 3.41-7.24% and 6.94-19.42% in 2017 and 2018, respectively. CV-A6 was the most important causative agent in all clinical symptoms (severe HFMD, HFMD, Herpangina and fever), accounting from 42.13% to 62.33%. EV-A71 only account for 0.36-2.05%. In severe HFMD, CV-A6 (62.33%), CV-A10 (11.64%), and CV-A16 (10.96%) were the major causative agent in 2018. EV-A71 inactivated vaccine has a good protective effect against EV-A71 and induced EVs infection spectrum changefully. EV-A71 vaccine has no or insignificant cross-protection effect on CV-A6, CV-A10, and CV-A16. Herein, developing 4-valent combined vaccines is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.